ChitogenX Inc. (CHNXF)
USD 0.01
(0.0%)
USD 0.01
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 | 3.87 Million CAD | -23.18% |
| 2023 | 5.04 Million CAD | 6.5% |
| 2022 | 4.73 Million CAD | -6.85% |
| 2021 | 5.08 Million CAD | 66.69% |
| 2020 | 3.05 Million CAD | 172.1% |
| 2019 | 1.12 Million CAD | 8.81% |
| 2018 | 1.03 Million CAD | -29.3% |
| 2017 | 1.45 Million CAD | 507.13% |
| 2016 | 240 Thousand CAD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 3.13 Million CAD | -39.83% |
| 2024 Q3 | 3.04 Million CAD | -2.62% |
| 2024 Q4 | 3.87 Million CAD | 27.09% |
| 2024 FY | 3.87 Million CAD | -23.18% |
| 2024 Q1 | 5.2 Million CAD | 3.17% |
| 2023 Q1 | 5.64 Million CAD | 19.11% |
| 2023 Q3 | 6.02 Million CAD | 3.92% |
| 2023 Q4 | 5.04 Million CAD | -16.21% |
| 2023 FY | 5.04 Million CAD | 6.5% |
| 2023 Q2 | 5.79 Million CAD | 2.69% |
| 2022 Q2 | 4.51 Million CAD | -3.56% |
| 2022 Q4 | 4.73 Million CAD | 1.94% |
| 2022 FY | 4.73 Million CAD | -6.85% |
| 2022 Q1 | 4.68 Million CAD | 1.52% |
| 2022 Q3 | 4.64 Million CAD | 2.83% |
| 2021 Q1 | 3.14 Million CAD | 20.62% |
| 2021 FY | 5.08 Million CAD | 66.69% |
| 2021 Q3 | 3.28 Million CAD | -0.45% |
| 2021 Q4 | 4.61 Million CAD | 40.62% |
| 2021 Q2 | 3.29 Million CAD | 4.77% |
| 2020 Q4 | 2.6 Million CAD | 32.5% |
| 2020 FY | 3.05 Million CAD | 172.1% |
| 2020 Q3 | 1.96 Million CAD | 32.68% |
| 2020 Q1 | 1.11 Million CAD | -3.72% |
| 2020 Q2 | 1.48 Million CAD | 33.45% |
| 2019 Q1 | 1.15 Million CAD | 2.88% |
| 2019 Q2 | 787.58 Thousand CAD | -31.6% |
| 2019 Q3 | 816.4 Thousand CAD | 3.66% |
| 2019 Q4 | 1.15 Million CAD | 41.47% |
| 2019 FY | 1.12 Million CAD | 8.81% |
| 2018 Q3 | 1.08 Million CAD | 38.55% |
| 2018 FY | 1.03 Million CAD | -29.3% |
| 2018 Q2 | 782.43 Thousand CAD | 46.89% |
| 2018 Q1 | 532.68 Thousand CAD | -39.46% |
| 2018 Q4 | 1.11 Million CAD | 3.24% |
| 2017 Q1 | 260 Thousand CAD | 8.33% |
| 2017 Q2 | 532.15 Thousand CAD | 104.67% |
| 2017 Q4 | 879.85 Thousand CAD | 58.77% |
| 2017 Q3 | 554.15 Thousand CAD | 4.13% |
| 2017 FY | 1.45 Million CAD | 507.13% |
| 2016 FY | 240 Thousand CAD | 0.0% |
| 2016 Q4 | 240 Thousand CAD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Accustem Sciences Inc. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 80.938% |
| Genus plc | 233.1 Million USD | 98.338% |
| LadRx Corporation | 33.6 Thousand USD | -11430.679% |
| Enzolytics Inc. | 996.33 Thousand USD | -288.924% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -412.428% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 70.185% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -2760.053% |
| Halberd Corporation | 150 Thousand USD | -2483.333% |
| Skye Bioscience, Inc. | 4.61 Million USD | 16.04% |
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 90.595% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -308.638% |
| Kadimastem Ltd | 891.22 Thousand USD | -334.794% |
| IMV Inc. | 28.88 Million USD | 86.584% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -167.922% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 86.982% |
| Zenith Capital Corp. | 10.22 Thousand USD | -37797.311% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 94.271% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -43.057% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 5.991% |
| EV Biologics, Inc. | 1.49 Million USD | -159.241% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 88.293% |
| Q BioMed Inc. | 4.1 Million USD | 5.717% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 33.999% |
| Biomind Labs Inc. | 735.54 Thousand USD | -426.822% |
| SQZ Biotechnologies Company | 27.47 Million USD | 85.894% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -2638.168% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -188.408% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -215.461% |
| CSL Limited | 12.18 Billion USD | 99.968% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -416.667% |
| CytoDyn Inc. | 30.07 Million USD | 87.116% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -1831.551% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 45.213% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -977.257% |
| HST Global, Inc. | 98.31 Thousand USD | -3841.252% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -864.293% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 93.26% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Affymax, Inc. | - USD | -Infinity% |
| Alpha Cognition Inc. | 1.22 Million USD | -217.526% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -1001.331% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 31.517% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| ContraFect Corporation | 2.88 Million USD | -34.502% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -61.612% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -711.518% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 91.066% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -336.342% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -32.235% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -1589.992% |
| NovAccess Global Inc. | 2.19 Million USD | -76.146% |
| Marizyme, Inc. | 18.71 Million USD | 79.297% |
| Mesoblast Limited | 118.7 Million USD | 96.735% |
| MultiCell Technologies, Inc. | 202.58 USD | -1912724.563% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -66.598% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -14966.682% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -515.004% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 97.741% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -71.583% |
| GB Sciences, Inc. | 1.75 Million USD | -120.257% |
| argenx SE | 20 Million USD | 80.625% |
| Resverlogix Corp. | 6.49 Million USD | 40.302% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -1416.088% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 91.495% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -28.049% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| ONE Bio Corp. | 19.71 Million USD | 80.345% |
| Genscript Biotech Corporation | 417.73 Million USD | 99.072% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -2506.724% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -1457.977% |
| Agentix Corp. | 50 Thousand USD | -7650.0% |
| Adynxx, Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 4.71 Million USD | 17.753% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -1448.872% |
| Cell Source, Inc. | 9.25 Million USD | 58.127% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -412.428% |
| Itoco Inc. | 228.37 Thousand USD | -1596.756% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -1736.711% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 22.236% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 50.447% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -3063.265% |
| Rebus Holdings, Inc. | 310 Thousand USD | -1150.0% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 18.167% |
| Mobile Lads Corp. | 484.28 Thousand USD | -700.15% |
| International Stem Cell Corporation | 4.17 Million USD | 7.252% |
| Bioxytran, Inc. | 1.92 Million USD | -101.299% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -6108.642% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -77.679% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 53.403% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 54.863% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -149.119% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -1345.896% |
| Neutra Corp. | 54.15 Thousand USD | -7055.255% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -111.749% |
| PureTech Health plc | 25.51 Million USD | 84.811% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -216.527% |
| IXICO plc | 472.02 Thousand USD | -720.935% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 75.002% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 93.776% |
| CSL Limited | 12.18 Billion USD | 99.968% |
| Cellectis S.A. | 92.77 Million USD | 95.823% |